The short version of Tuftsin analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
This helium-nitrogen mixture was injected and stored in the Cliffside gas field until needed, at which time it was further purified. By 1995, a billion cubic meters of the gas had been collected and the reserve was US$1.4 billion in debt, prompting the Congress of the United States in 1996 to discontinue the reserve. The resulting Helium Privatization Act of 1996 (Public Law 104–273) directed the United States Department of the Interior to empty the reserve, with sales starting by 2005. Helium produced between 1930 and 1945 was about 98.3% pure (2% nitrogen), which was adequate for airships. In 1945, a small amount of 99.9% helium was produced for welding use. By 1949, commercial quantities of Grade A 99.95% helium were available. For many years, the United States produced more than 90% of commercially usable helium in the world, while extraction plants in Canada, Poland, Russia, and other nations produced the remainder. In the mid-1990s, a new plant in Arzew, Algeria, producing 17 million cubic metres (600 million cubic feet) began operation, with enough production to cover all of Europe's demand. Meanwhile, by 2000, the consumption of helium within the U.S. had risen to more than 15 million kg per year. In 2004–2006, additional plants in Ras Laffan, Qatar, and Skikda, Algeria were built. Algeria quickly became the second leading producer of helium. Through this time, both helium consumption and the costs of producing helium increased. From 2002 to 2007 helium prices doubled.
The process of termination by Rho factor is regulated by attenuation and antitermination mechanisms, competing with elongation factors for overlapping utilization sites (ruts and nuts), and depends on how fast Rho can move during the transcription to catch up with the RNA polymerase and activate the termination process. Inhibition of Rho dependent termination by bicyclomycin is used to treat bacterial infections. The use of this mechanism along with other classes of antibiotics is being studied as a way to address antibiotic resistance, by suppressing the protective factors in RNA transcription while working in synergy with other inhibitors of gene expression such as tetracycline or rifampicin.
Wanted immunogenicity typically relates to vaccines, where the injection of an antigen (the vaccine) provokes an immune response against the pathogen, protecting the organism from future exposure. Immunogenicity is a central aspect of vaccine development. Unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug-antibodies (ADAs), inactivating the therapeutic effects of the treatment and potentially inducing adverse effects. A challenge in biotherapy is predicting the immunogenic potential of novel protein therapeutics. For example, immunogenicity data from high-income countries are not always transferable to low-income and middle-income countries. Another challenge is considering how the immunogenicity of vaccines changes with age. Therefore, as stated by the World Health Organization, immunogenicity should be investigated in a target population since animal testing and in vitro models cannot precisely predict immune response in humans. Antigenicity is the capacity of a chemical structure (either an antigen or hapten) to bind specifically with a group of certain products that have adaptive immunity: T cell receptors or antibodies (a.k.a. B cell receptors). Antigenicity was more commonly used in the past to refer to what is now known as immunogenicity, and the two terms are still often used interchangeably. However, strictly speaking, immunogenicity refers to the ability of an antigen to induce an adaptive immune response.
The Celtic Boii settled there and the region was first mentioned on the map of Ptolemaios in the 2nd century AD. The Germanic tribe of the Marcomanni dominated the entire core of the region in later centuries. Those tribes already built cities like Brno, but moved west during the Migration Period. In the 7th century AD Slavic people moved in and were united under Samo's realm. Later in the High Middle Ages Germans settled into the less populated border region.
March 26: Residents in France, regardless of nationality, are subject to personal tax if they enjoy their rights. For women, this applies to single women with a profession or personal income living independently, women separated from their husbands, and widows. April 19: For a man to be a voter, his and his wife's assets are considered in calculating contributions. If a woman is separated, divorced, or widowed, her contributions are associated with a close male relative's assets (excluding illegitimate children) at her discretion. 1832
Sources: en.wikipedia.org
===== Guyana ===== In February 2024, president Lula announced he would visit Guyana and meet president Irfaan Ali to discuss topics such as the Essequiba border dispute with Venezuela and a potential hydro-power energy sharing agreement between Guyana and Brazil. On 28 February, Lula spoke at a CARICOM summit in Georgetown in which he said he intends Brazil to resume having diplomatic missions in the Caribbean nations. Lula added Brazil was making a monetary contribution to the Caribbean Development Bank.
=== Phase 1 === AZD-4041 – orexin OX1 receptor antagonist – opioid-related disorders BI-1356225 – ghrelin O-acyltransferase (GOAT) inhibitor – opioid-related disorders Cebranopadol (GRT-6005; PRK-101; TRN-228) – μ-opioid receptor agonist, nociceptin receptor agonist – substance-related disorders CSX-1004 – monoclonal antibody against fentanyl – opioid-related disorders Dimethyltryptamine/harmine (DMT/harmine; RE-01) – combination of dimethyltryptamine (DMT) (serotonin 5-HT2A receptor agonist and serotonergic psychedelic) and harmine (monoamine oxidase inhibitor (MAOI) and other actions) – cocaine-related disorders DPI-125 (MCP-201) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – opioid-related disorders Ibuprofen/ketotifen (SJP-005) – combination of ibuprofen (cyclooxygenase (COX) inhibitor/NSAID) and ketotifen (histamine H1 receptor antagonist, other actions) – opioid-related disorders Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – opioid-related disorders KNX-100 (SOC-1) – oxytocin-like drug / indirect oxytocin receptor modulator – opioid-related disorders, substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – cocaine-related disorders MEB-1170 – μ-opioid receptor biased agonist – opioid-related disorders Mebufotenin (5-MeO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, and serotonergic psychedelic – substance use disorders MST-01 – undefined mechanism of action – smoking withdrawal Nalmefene (AV-104; TH-104) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Naltrexone implantable pellets (BICX-102, BICX-104) – opioid receptor antagonist – alcoholism, opioid-related disorders, substance-related disorders Nezavist (DCUK-OEt) – peripherally selective GABAA receptor positive allosteric modulator (etomidate site) – alcoholism Noribogaine (DMX-1001) – various actions – alcoholism NRS-033 (nalmefene prodrug) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders OMS-527 (OMS-182399; OMS527) – phosphodiesterase PDE7 inhibitor – cocaine-related disorders Psilocybin (MLS-101/MLS101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – opioid-related disorders Smoking cessation therapeutics - Astraea Therapeutics – nicotinic acetylcholine receptor antagonists – smoking withdrawal SXC-2023 – cystine/glutamate transporter (SLC7A11) – cocaine-related disorders Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – opioid-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – cocaine-related disorders, substance-related disorders
Compared to the City of Toronto as a whole, industry in the district is similar in all labour force categories, save for manufacturing which is higher in the district, and professional, scientific and technical services which are lower. Notable companies that have their headquarters in the district include Toyota Canada, Owens Corning (Toronto), Elizabeth Grant International, Enterprise Holdings, Inc., Thomson Carswell, Bell Media, Teva Canada, Cinram, Royal Doulton, SKF, Amphenol, Dart Canada, Mastermind Toys, Alfa Laval, President's Choice Financial, Aviva, Yellow Pages Group, Telus, and Lee Kum Kee Canada. The pizza chains 241 Pizza and Pizza Nova have their headquarters in Scarborough. Amazon opened a new fulfillment centre in north Scarborough in 2020. Large companies that have moved out of Scarborough include: General Motors Canada Van Assembly plant (1993) and Eli Lilly Canada (2019). A high-density business district has been built up in Scarborough City Centre. Points of interest in the area include Scarborough Town Centre, Albert Campbell Square, Street Eats Market, many surrounding stores, and government and business offices. The area has become one of Toronto's secondary business districts outside of Downtown Toronto.
Jammu and Kashmir has two major airports at the two capitals of the territory: Jammu Airport at Jammu and Srinagar Airport at Srinagar, which is also the only international airport in the territory. These airports have regular flights to Delhi, Mumbai, Bangalore, Chandigarh and other major cities of the country. In 2025, Jammu Airport began undergoing expansion, including a 45,000 m² terminal with night-landing capabilities. Srinagar Airport is also undergoing expansion, with the construction of a 71,500 m² terminal. In 2025, Udhampur Air Force Station was assessed by a government committee for the feasibility of launching commercial flight operations as an airport. An aerial ropeway for Shankaracharya Temple in Srinagar is planned for completion in 2026 and will cut ascent time from 30 minutes to five minutes.
=== Fosfomycin === Several antimicrobial drugs have been tested for the effective treatment of CRE. Fosfomycin is an antimicrobial agent that acts to inhibit UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) which catalyzes one of the early steps of bacterial cell wall synthesis, and is effective against gram-negative and -positive aerobic bacteria, such as CRE. A meta-analysis of 17 studies investigating the clinical effectiveness of fosfomycin in four multidrug-resistant strains of Enterobacteriaceae found 11 which reported that over 90% of bacterial isolates were susceptible to fosfomycin. The elevated level of antimicrobial activity by fosfomycin can be attributed to the fact that resistance to this antibiotic in Enterobacteriaceae is chromosomally encoded and not plasmid-mediated. This causes a decreased capacity for survival in the bacteria. Bacteria that are naturally resistant to fosfomycin are less robust and less pathogenic.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.